NCT07539428

Brief Summary

This study conducted a randomized controlled trial using clinical vignettes to evaluate differences in the quality of PD management among two large language model-assisted workflows and a physician-only decision-making process, and to identify potential risks (e.g., generating clearly erroneous or even harmful suggestions).

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P75+ for not_applicable

Timeline
1mo left

Started Apr 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress59%
Apr 2026May 2026

First Submitted

Initial submission to the registry

April 5, 2026

Completed
Same day until next milestone

Study Start

First participant enrolled

April 5, 2026

Completed
15 days until next milestone

First Posted

Study publicly available on registry

April 20, 2026

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 30, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 30, 2026

Last Updated

April 20, 2026

Status Verified

April 1, 2026

Enrollment Period

2 months

First QC Date

April 5, 2026

Last Update Submit

April 13, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Management Reasoning

    Percent correct (range: 0 to 100) for each case.

    Within 90-min study

Secondary Outcomes (4)

  • Domain-Specific Scores

    within 90-min study.

  • Severity of Potential Harm

    Within 90-min study.

  • Time Spent on Management

    Within 90-min study.

  • Self-Reported Confidence per Case

    Within 90-min study.

Other Outcomes (2)

  • Total vignette performance score of LLM generated answers

    Within 90-min study.

  • Severity of Potential Harm of LLM-generated answers

    Within 90-min study.

Study Arms (3)

Phys Group

NO INTERVENTION

Participants could search for relevant knowledge, but access to large language model (LLM)-related websites was prohibited.

Phys+DS Group

PLACEBO COMPARATOR

Participants had access to both the web and the DeepSeek interface.

Other: Generalized LLM tools such as deepseek

Phys+PD-LLM Group

EXPERIMENTAL

Participants had access to the web and a specialized PD-LLM provided by the First Affiliated Hospital of Sun Yat-sen University.

Other: Peritoneal dialysis-specialized large language model.

Interventions

The peritoneal dialysis-specialized large language model (PD-LLM) used in this study was jointly developed by the Department of Nephrology at the First Affiliated Hospital of Sun Yat-sen University and Digital Health China (DHC).

Phys+PD-LLM Group

Participants were permitted to ask the LLM any questions related to the clinical scenarios. However, they were explicitly instructed to critically evaluate the model's suggestions and to take full responsibility for the final clinical plans.

Phys+DS Group

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Internal medicine or nephrology standardized training residents, licensed residents, or attending physicians.
  • Independent experience in PD management ≤ 3 years.
  • Provided signed informed consent and agreed to comply with the trial procedures.

You may not qualify if:

  • Direct involvement in the development or training of the specialized PD large language model, or in the construction of the clinical scenarios/ scoring criteria used in this trial.
  • Participation in the pilot testing of all clinical scenarios used in this trial.
  • Inability or unwillingness to access the study platform or use online resources during the study period.
  • Experienced PD experts.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sixiu Chen

Guangzhou, Guangdong, 510080, China

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Vice President

Study Record Dates

First Submitted

April 5, 2026

First Posted

April 20, 2026

Study Start

April 5, 2026

Primary Completion (Estimated)

May 30, 2026

Study Completion (Estimated)

May 30, 2026

Last Updated

April 20, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations